Biomarkers Companies

The biomarkers market is expected to reach USD 104.15 billion in 2030 from USD 62.39 billion in 2025, at a CAGR of 10.8% during the forecast period. The major factors driving the growth of this market include the increasing use of biomarkers in drug discovery and development, as well as the rising prevalence of cancer, which supports the need for early diagnosis and targeted therapies. These factors offer new growth opportunities, such as the growing focus on personalized medicine, where biomarkers enable personalized treatment decisions, and enhanced collaboration between healthcare providers and industry players to accelerate biomarker research and clinical application.

The global biomarkers market is fragmented, and the key market players have adopted various strategies such as new product launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions to strengthen their position in the global biomarkers market. For instance, in January 2025, Quanterix Corporation announced the acquisition of Akoya Biosciences, combining their technologies to offer integrated solutions for detecting blood- and tissue-based protein biomarkers. This acquisition helps expand their capabilities and market reach. Product launches also contribute to market growth, such as Roche’s launch of the VENTANA MET (SP44) RxDx Assay in May 2025, identifying patients with non-small cell lung cancer for targeted therapy. Developments such as the September 2024 collaboration between QIAGEN and Eli Lilly aim to develop a diagnostic test for APOE genotyping to identify patients at risk for Alzheimer’s.

To know about the assumptions considered for the study download the pdf brochure

Moreover, emerging companies are utilizing AI and ML to carve a niche in the biomarker market. For instance, in April 2025, Ignite Biomedical and Liquid Biosciences partnered to discover new biomarkers for substance use disorder. The companies are using AI to improve diagnosis and treatment options. These strategies enable companies to combine expertise, access new technologies, and address clinical needs, strengthening their position in the biomarker market.

F. Hoffmann-La Roche Ltd (Switzerland)

F. Hoffmann-La Roche Ltd is a major player in the global biomarker market, leveraging its integrated diagnostics-pharmaceutical business model, strong geographical presence, and ongoing innovation. The company operates in two segments: Diagnostics and Pharmaceuticals, with the Diagnostics division encompassing Core Lab, Molecular Lab, Pathology Lab, Point of Care, and Diabetes Care. These divisions provide biomarker-based assays, digital platforms, and companion diagnostics for applications in oncology, cardiology, neurology, infectious diseases, and diabetes.

In 2023, Roche's Diagnostics division processed over 29 billion tests across more than 100,000 platforms, reflecting strong global demand. The company launched over 20 diagnostic assays between 2022 and May 2025, including the FDA-approved VENTANA MET (SP44) RxDx Assay for non-squamous non-small cell lung cancer. Roche also actively pursues partnerships, such as collaborations with PathAI for AI-based pathology algorithms and with Neuron23 to utilize digital biomarkers in Parkinson’s disease trials. Roche’s integration of diagnostic development, test delivery, and data platforms, along with its global reach and AI-enabled R&D, enhances its leadership in the biomarker market.

Merck KGaA (Germany)

Merck KGaA is a major player in the biomarker market through its Life Science segment, which provides biomarker assays, consumables, software, and services for research and diagnostics. The Science & Lab Solutions division focuses on biomarker discovery, validation, and analysis. With a global presence and subsidiaries like EMD Millipore Corporation and Merck Biosciences AG, Merck has strengthened its position through strategic partnerships. In January 2025, it collaborated with Qpentions Labworks to automate assay workflows with the Flex robotic workstation, enhancing protein sample preparation. Additionally, in June 2024, Merck partnered with the Michael J. Fox Foundation to support the SMCXPRQ immunoassay platform for detecting low-abundance biomarkers related to early Parkinson's disease. This focus on automation and disease-specific advancements highlights Merck's significant role in the global biomarker market.

Market Ranking

The biomarker market is highly fragmented, with five major players collectively holding only 8–10% of the market share. F. Hoffmann-La Roche Ltd has expanded its biomarker portfolio by launching over 20 diagnostic assays from 2022 to 2025 and has integrated artificial intelligence through partnerships, such as its collaboration with PathAI. Merck KGaA has enhanced its presence by offering highly sensitive immunoassay platforms and automating biomarker discovery workflows through its alliance with Qpentions Labworks. Thermo Fisher Scientific, Inc. continues to lead in proteomics and genomic biomarker research with its high-throughput sequencing tools and multiplex assay platforms. Abbott concentrates on disease-specific biomarker diagnostics, particularly in the cardiovascular and infectious disease segments, by continuously developing products and ensuring global accessibility. QIAGEN is advancing the market with its molecular diagnostics and bioinformatics platforms, backed by strategic partnerships and the co-development of companion diagnostics.

The remaining 90–92% of the market is shared among regional and emerging vendors, creating opportunities for niche and early-stage biomarker developers. Market growth is further propelled by the rising demand for personalized medicine, ongoing technological innovation, and expanding clinical research across various therapeutic areas.

Related Reports:

Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious, Neurological), Application (Diagnostic, Research) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com